New Bispecific Antibody Approved for Tough-to-Treat Lymphoma
Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate
Source: medpagetoday.com
Page 7 - Lymphoma Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lymphoma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lymphoma Program Today - Breaking & Trending Today
FDA Approves Glofitamab-gxbm to Treat Adults With Relapsed/Refractory DLBCL
Glofitamab is the first bispecific antibody with a fixed-duration treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Source: ajmc.com
Combination treatment gives 94 percent PFS in Hodgkin lymphoma
A PD-1 checkpoint inhibitor plus chemotherapy is expected to become new standard of care for advanced lymphoma, based on Phase III trial data.
Source: europeanpharmaceuticalreview.com
City of Hope Researcher Leads Successful Phase 3 Trial for Hodgkin Lymphoma Treatment
Miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Source: miragenews.com
SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma
A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.
Source: news-medical.net